Bryce Patrick Portier
Research Subjects
Research Interests
Bryce Patrick Portier has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Bhavin Shah
4 shared publications- Christopher Leveque
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
4 shared publications - Jun Qi
Department of Cancer Biology Dana‐Farber Cancer Institute Boston MA USA
4 shared publications - Kapil N. Bhalla
The University of Texas M.D. Anderson Cancer Center, Houston, USA
4 shared publications Santhana G.T. Devaraj
4 shared publications- Sunil Kumar Sharma
Department of Chemistry, University of Delhi, Delhi 110007, India
4 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data Supplement from BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Figure Legends for Supplemental Data.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData Supplement from BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Figure Legends for Supplemental Data.
- 14 August 2017
- Published by Springer Nature
- p. 93-108
Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)
- 14 August 2017
- Published by Springer Nature
- p. 93-108
Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)
- 14 August 2017
- Published by Springer Nature
- p. 131-143
Next-Generation and Third-Generation Sequencing of Lung Cancer Biomarkers
- 14 August 2017
- Published by Springer Nature
- p. 131-143
Next-Generation and Third-Generation Sequencing of Lung Cancer Biomarkers
- Open Access
- 30 August 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-11
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
- 30 August 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-11
Open AccessMET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
- 1 February 2014
- Published by Elsevier in Laboratory Investigation
- Vol. 27 (2) , 314-327
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics
- 1 February 2014
- Published by Elsevier in Laboratory Investigation
- Vol. 27 (2) , 314-327
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics
- Open Access
- 1 May 2011
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 135 (5) , 544-557
Molecular Pathology of Breast Cancer: The Journey From Traditional Practice Toward Embracing the Complexity of a Molecular Classification
Context .—Adenocarcinoma of the breast is the most frequent cancer affecting women in both developed and developing regions of the world. From the moment of clinical presentation until the time of pathologic diagnosis, patients affected by this disease will face daunting questions related to prognosis and treatment options. While improvements in targeted therapies have led to increased patient survival, these same advances have created the imperative to accurately stratify patients to achieve maximum therapeutic efficacy while minimizing side effects. In this evolving era of personalized medicine, there is an ever-increasing need to overcome the limitations of traditional diagnostic practice. Objective .—To summarize the molecular diagnostics traditionally used to guide prognostication and treatment of breast carcinomas, to highlight published data on the molecular classification of these tumors, and to showcase molecular assays that will supplement traditional methods of categorizing the disease. Data Sources .—A review of the literature covering the molecular diagnostics of breast carcinomas with a focus on the gene expression and array studies used to characterize the molecular signatures of the disease. Special emphasis is placed on summarizing evolving technologies useful in the diagnosis and characterization of breast carcinoma. Conclusions .—Available and emerging molecular resources will allow pathologists to provide superior diagnostic, prognostic, and predictive information about individual breast carcinomas. These advances should translate into earlier identification and tailored therapy and should ultimately improve outcome for patients affected by this disease.
- 1 May 2011
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 135 (5) , 544-557
Open AccessMolecular Pathology of Breast Cancer: The Journey From Traditional Practice Toward Embracing the Complexity of a Molecular Classification
Context .—Adenocarcinoma of the breast is the most frequent cancer affecting women in both developed and developing regions of the world. From the moment of clinical presentation until the time of pathologic diagnosis, patients affected by this disease will face daunting questions related to prognosis and treatment options. While improvements in targeted therapies have led to increased patient survival, these same advances have created the imperative to accurately stratify patients to achieve maximum therapeutic efficacy while minimizing side effects. In this evolving era of personalized medicine, there is an ever-increasing need to overcome the limitations of traditional diagnostic practice. Objective .—To summarize the molecular diagnostics traditionally used to guide prognostication and treatment of breast carcinomas, to highlight published data on the molecular classification of these tumors, and to showcase molecular assays that will supplement traditional methods of categorizing the disease. Data Sources .—A review of the literature covering the molecular diagnostics of breast carcinomas with a focus on the gene expression and array studies used to characterize the molecular signatures of the disease. Special emphasis is placed on summarizing evolving technologies useful in the diagnosis and characterization of breast carcinoma. Conclusions .—Available and emerging molecular resources will allow pathologists to provide superior diagnostic, prognostic, and predictive information about individual breast carcinomas. These advances should translate into earlier identification and tailored therapy and should ultimately improve outcome for patients affected by this disease.
- 1 July 2006
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 155 (1) , 134-142
Rapid assay for quantitative measurement of apoptosis in cultured cells and brain tissue
- 1 July 2006
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 155 (1) , 134-142
Rapid assay for quantitative measurement of apoptosis in cultured cells and brain tissue